To determine the incidence/one year relapse from remission and associated factors in patients with T2DM. A total of 48,320 Japanese patients with T2DM with HbA1c ≥6.5% and/or glucose-lowering drug prescription were identified from databases of specialists’ clinics from 1989 and followed until September 2022. Remission was diagnosed according HbA1c <6.5% at least 3 months after cessation of glucose-lowering drug and relapse as failing to maintain remission for 1 year. Factors associated with remission/relapse were evaluated by logistic regression analysis. The overall incidence of remissions per 1,000 person-years was 10.5. Such values for those with HbA1c 6.5-6.9%, taking no glucose-lowering drugs at baseline, and a ≥10% BMI reduction in one year were 27.8, 21.7, 48.2, respectively (Fig.). Shorter duration, lower baseline HbA1c, higher BMI at baseline, higher BMI reduction at one year, and no glucose-lowering drugs at baseline were significantly associated with remission. Among 3,677 persons with remission, approximately two-thirds (2,490) relapsed within one year. Longer duration, lower BMI at baseline, and lower BMI reduction at one year were significantly associated with relapse. Results showed that the incidence of remission and predictors of relapse, especially baseline BMI were greatly different in East Asians compared to reports in Western populations.
K.Fujihara: None. L.Khin: None. K.Murai: None. Y.Mitsuma: None. K.Yamazaki: None. H.Maegawa: None. S.Tanaka: Research Support; Novo Nordisk. S.Kodama: None. H.Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd.
Japan Society for the Promotion of Science (21K11569)
